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Abstract
The tumor microenvironment is fundamental to cancer progression,
and the influence of its mechanical properties is increasingly being
appreciated. Tamoxifen has been used for many years to treat estro-
gen-positive breast cancer. Here we report that tamoxifen regulates
the level and activity of collagen cross-linking and degradative
enzymes, and hence the organization of the extracellular matrix, via
a mechanism involving both the G protein-coupled estrogen receptor
(GPER) and hypoxia-inducible factor-1 alpha (HIF-1A). We show that
tamoxifen reduces HIF-1A levels by suppressing myosin-dependent
contractility and matrix stiffness mechanosensing. Tamoxifen also
downregulates hypoxia-regulated genes and increases vasculariza-
tion in PDAC tissues. Our findings implicate the GPER/HIF-1A axis as
a master regulator of peri-tumoral stromal remodeling and the
fibrovascular tumor microenvironment and offer a paradigm shift
for tamoxifen from a well-established drug in breast cancer
hormonal therapy to an alternative candidate for stromal targeting
strategies in PDAC and possibly other cancers.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common type
of pancreatic cancer and one of the leading causes of cancer-related
death despite substantial efforts in recent years aimed at optimizing
therapies. PDAC is distinguished by a strong desmoplasia in the
tumor microenvironment or stroma that has been associated with
aggressiveness of the disease [1], but has also been reported to
restrain tumor growth [2,3], suggesting that stromal contribution
varies depending on the context. Therefore, there is an urgent need
for studies that characterize the structure of this desmoplastic stroma
in order to decipher its complex and dynamic interaction with the
tumor. PDAC is one of the stiffest solid carcinomas, which intuitively
leads to the idea of disrupted mechanical communication between
cancer and stromal cells and unbalanced tissue tension within the
extracellular matrix (ECM). Thus, PDAC can be viewed as a complex
multifaceted disease of altered mechanobiology. Indeed, a recent
study has shown that enhanced mechanosignaling in the tumor
epithelia can promote PDAC progression in mouse models, overriding
the need for p53 mutation [4], while another study showed that
targeting focal adhesion kinase in vivo could reduce fibrosis and
therefore sensitize pancreatic cancer cells to immunotherapy [5].
The strong desmoplasia severely impacts vascular function in
PDAC, which hosts a remarkably hypovascularized tumor microen-
vironment. This dysfunctional vasculature has represented a major
hurdle for chemotherapy delivery and has been used as a diagnostic
tool in PDAC imaging for many years [1]. PDAC, like other hypo-
vascularized tumors, has substantial hypoxic areas [6,7]. The abil-
ity of cancer and stromal cells to thrive under these hostile
conditions of subpar oxygen supply depends on their capacity to
trigger pathways necessary for development under hypoxic condi-
tions. The hypoxia-inducible factor (HIF) pathway is the main
mechanism activated in cells to adapt to hypoxia. Under these
conditions, hypoxia-inducible factor-1 alpha (HIF-1A) translocates
to the nucleus and binds to the hypoxia-response elements, thereby
activating the expression of genes that control multiple functions in
cells such as metabolism, survival, proliferation and apoptosis,
migration, energetic balance, and pH [8]. Notably, PDAC seems to
progress without the need of excessive angiogenesis and a recent
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study suggests a lack of correlation between the hypovascular
nature of PDAC and hypoxia [9,10].
Pancreatic stellate cells (PSCs) are the main group of resident
cells in the stroma and the key drivers of the desmoplastic reaction
[11]. In PDAC, like other cancer-associated fibroblasts (CAFs), PSCs
are activated and adopt a myofibroblastic phenotype with high
contractile activity, leading to stiffening of the ECM and extensive
deposition of ECM proteins such as collagen and fibronectin [12–
14]. PSCs orchestrate ECM organization, not only via force-mediated
matrix remodeling or through the synthesis and deposition of ECM
proteins, but also by regulated secretion of elevated levels of matrix
cross-linking enzymes such as lysyl oxidase (LOX) and degradative
proteases such as metalloproteinases (MMPs) and their inhibitors
(tissue inhibitor of metalloproteinases, TIMPs) [11,15,16]. The
controlled balance between these cross-linking and degradative
enzymes regulates ECM architecture in normal pancreas, but loss of
this balance in PDAC triggers and sustains the desmoplastic reaction
[12]. Interestingly, the LOX/hypoxia axis correlates with poor prog-
nosis in PDAC patients and targeting this axis in PDAC mice has
been shown to decrease tumorigenesis, augment chemotherapy effi-
cacy, and decrease metastasis [17]. Moreover, treating PDAC mouse
models with ATRA (all trans-retinoic acid), which abrogates force-
mediated ECM remodeling by PSCs [16], increased vascular density
and decreased hypoxia [18].
Tamoxifen has been used for many years to treat breast cancers
based on its genomic effect on the nuclear estrogen receptors. Here
we report a previously unidentified mechanism that is independent
of the nuclear estrogen receptors and involves the G protein-
coupled estrogen receptor (GPER) and hypoxia-inducible factor-1
alpha (HIF-1A). We show that tamoxifen reduces the adaptive
response of PDAC to hypoxia via a mechanical downregulation of
HIF-1Α, and increases vascularization in PDAC mouse models.
Tamoxifen tunes the balance between cross-linking (LOX) and
degrading enzymes (MMPs) secreted by PSCs to modulate collagen
and fibronectin fiber architecture in the tumor microenvironment.
Tamoxifen treatment also decreases the fitness of pancreatic cancer
cells to cope with hypoxic conditions via mechanical downregula-
tion of HIF-1A.
Results
Tamoxifen treatment induces changes in protein content of
PDAC tissues and gene expression profiles in PSCs
We treated KPC mice (Pdx-1 Cre, KRasG12D/+, p53R172H/+), which
are known to recapitulate the clinical and histological features of
human PDAC [2], with 2 mg of tamoxifen, and used quantitative
shotgun proteomic analysis to investigate whether tamoxifen treat-
ment induced changes in the protein content of PDAC tissues. This
dose in mice (100 mg/kg) produces a tamoxifen serum concentra-
tion around 0.5 lM, which corresponds to the serum concentration
found in humans after administration of clinical doses of 20 mg/day
[19]. In total, 110 proteins showed statistically significant changes
(Fig EV1 and Dataset EV1–EV3). From this group, more than half of
the downregulated proteins are involved in ECM organization, cell
adhesion, and wound healing. These data have been deposited in
the PeptideAtlas under the reference PASS01070.
To study the effect of tamoxifen on the main resident cells in the
tumor microenvironment, PSCs were treated with 5 lM of tamox-
ifen as higher doses showed toxicity (Fig EV2). RNA sequencing
and gene profile analysis of control and treated PSCs showed that
from the nearly 20,000 expressed genes, 649 were upregulated and
688 downregulated (Fig EV3, Dataset EV4–EV6). The larger group
of upregulated genes is associated with blood vessel morphogenesis,
and the downregulated genes are involved in ECM organization, cell
migration, cell–ECM adhesion, and the response to hypoxia. These
data have been deposited in the European Nucleotide Archive,
accession number ERP023834.
Tamoxifen reduces hypoxia and increases vascularization in
PDAC tissues
In order to investigate the effect of tamoxifen treatment on hypoxia
and vascularization levels in PDAC tissues, we used GLUT1 and
CD31 immunofluorescence staining of pancreatic tissues from KPC
mice treated with 2 and 5 mg of tamoxifen (Fig 1A). The level of
the hypoxia marker GLUT1 was significantly reduced from control
mice to mice treated with 5 mg (fourfold reduction) in a dose-
dependent fashion (Fig 1B). We also observed a pronounced reduc-
tion in Glut1 content in PDAC tissues from treated mice relative to
control using quantitative proteomics analysis (Fig 1C). A twofold
increase in vascularization was observed in mice treated with the
highest doses compared to untreated mice (Fig 1D).
RNA sequencing of PSCs revealed more than 25 hypoxia-related
genes downregulated and more than 30 blood vessel morphogenesis
genes upregulated after tamoxifen treatment (Figs 1E and F, and
EV3). We then focused on the hypoxia-inducible factor (HIF) and
vascular endothelial growth factor (VEGF) families as key players
associated with hypoxia and blood vessels respectively
(Appendix Fig S1). For the HIF family, we found that while HIF-3A
did not change, HIF-1A was significantly reduced and HIF-2A (also
known as EPAS1) was significantly upregulated. We observed an
increase in the expression levels of VEGFB and a downregulation of
VEGFC. qPCR was used to validate RNA sequencing data that
showed a clear trend but did not display significant differences.
The analysis of the downregulated hypoxia-related genes
revealed a map of interactions centered in HIF-1A (Appendix Fig
S2). We observed a nearly 70% reduction in HIF-1A levels in PDAC
tissues from KPC mice treated with 5 mg of tamoxifen relative to
control KPC mice treated with vehicle (Fig 1G and H). We also con-
firmed that the effect of tamoxifen on the HIF-1A levels of PSCs is
mediated by GPER, as the use of GPER antagonist (but not ER antag-
onist) returned the HIF-1A values to the levels found in control PSCs
(Fig 1I). We used immunoblotting to investigate the effect of tamox-
ifen on the levels of HIF-1A in PSCs and observed an overall 25%
reduction in the 3 main HIF-1A isoforms (1–3) and also in the post-
translationally modified HIF-1A (Fig 1J and Appendix Fig S3). Taken
together, these data show that tamoxifen induces the expression of
genes that promote blood vessels formation and downregulates
hypoxia-related genes, with many of them converging in HIF-1A.
Tamoxifen decreases LOX-L2 levels in PSCs and PDAC tissues
The lysyl oxidase (LOX) gene encodes the lysyl oxidase family
of extracellular copper-dependent enzymes that catalyses the
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cross-linking of collagen fibers. Within this family, LOX is the most
characterized member and LOX-L2 (lysyl oxidase homolog-2) has
been comprehensively documented to participate in ECM remodel-
ing of the tumor and fibrotic microenvironments. All LOX members
contain a highly conserved copper binding and catalytic C-terminal
domain, responsible for the cross-linking function of these enzymes
[20]. The LOX family has been known to promote fibrosis and
tumorigenesis, and accumulated evidence supports the use of b-
aminopropionitrile (bAPN) and simtuzumab to inhibit LOX and
LOX-L2 activities in fibrosis and cancer [13]. These inhibitors have
reverberated across the fields of inflammation and cancer as poten-
tial agents to restore normal collagen architecture and mechanical
tissue homeostasis [21].
Increased expression of LOX-L2 has been reported in human
PDAC tissues with respect to normal stroma, and elevated LOX/
hypoxia is associated with the shortest patient survival [17,22].
Given that we observed a significant downregulation of LOX-L2 after
tamoxifen treatment in the analysis of the gene profile of PSCs, and
LOX-L2 is elevated in PDAC and regulated by HIF-1A [23,24], we
focused first on this member of the LOX family and tested the LOX-
L2 levels in PSCs following tamoxifen treatment. We observed a
threefold decrease of LOX-L2 at the gene and protein levels
compared to untreated control (Fig 2A and B). This effect was main-
tained when we used an estrogen receptor (ER) antagonist but not a
GPER antagonist, which supports the notion that tamoxifen reduces
LOX-L2 expression via GPER.
Next, we examined the effect of tamoxifen treatment on the
expression levels of all LOX family members in PSCs and PDAC
tissues from KPC mice using RNA sequencing, qPCR, and quantita-
tive proteomics analysis. Except for LOX-L1, we observed a marked
decrease in the mRNA levels of all members expressed by PSCs, and
there was a significant downregulation in the protein content of
LOX-L2 and LOX-L3 in tissues coming from KPC mice treated with
5 mg tamoxifen (Fig 2C–E). This dose-dependent significant
decrease of LOX-L2 in tissues was also validated by dual staining of
LOX-L2 and aSMA (marker of PSCs) immunofluorescence analysis
(Fig 2F and G).
In order to gain insights in the mechanism by which tamoxifen
decreases LOX-L2 levels in PSCs, we cultured these cells in poly-
acrylamide (PAA) matrices of varying rigidities: 1 kPa (soft matrix)
or 25 kPa (stiff matrix) as previously reported [25,26]. LOX-L2 and
HIF-1A levels were significantly upregulated in PSCs cultured on
stiff compared to the soft matrices, and tamoxifen-treated PSCs
cultured on stiff substrates expressed LOX-L2 and HIF-1A levels
comparable to the ones shown on the soft matrices (Fig 2H). These
results led us to investigate whether increased contractility in PSCs
could per se increase the levels of expression of LOX-L2 and HIF-1A.
We transfected PSCs with a myosin isoform that was constitutively
active and monitored the levels of LOX-L2 and HIF-1A from PSCs
cultured on glass. Both LOX-L2 and HIF-1A were significantly upreg-
ulated in PSCs transfected with active myosin compared to the
values from control PSCs (Fig 2I). We used micropillars sensors as
described previously [16] to observe that tamoxifen decreased
myosin-dependent contractility in PSCs, with the endogenous forces
applied to the matrix by tamoxifen-treated PSCs comparable to the
forces observed with the use of blebbistatin (BBI), a strong inhibitor
of myosin activation and cell contractility (Fig 2J). This decrease in
traction forces was maintained with tamoxifen treatment in the
presence of the ER antagonist but suppressed when the GPER antag-
onist was used. We also used siRNA against HIF-1A to knockdown
HIF-1A expression in PSCs (Appendix Fig S4) and found that under
these conditions, tamoxifen treatment did not reduce LOX-L2 levels
beyond the values observed for PSCs transfected with siRNA against
HIF-1A (Fig 2K). Collectively, these data show that tamoxifen
decreases LOX-L2 in PSCs and PDAC tissues via GPER signaling and
through a mechanism that involves mechanical downregulation of
HIF-1A via myosin-dependent PSC contractility and matrix stiffness
mechanosensing.
Tamoxifen modulates collagen synthesis and matrix collagen
remodeling by PSCs
In order to study the effect of tamoxifen on the ability of PSCs to
remodel the matrix, we used 3D organotypic assays in which PSCs
were embedded within matrigel collagen gels and allowed to
remodel the matrix for 72 h. Then, second harmonic generation
(SHG) imaging was used to visualize type I fibrillar collagen (re-
ferred to as collagen hereafter) (Fig 3A). Untreated control PSCs
modified the topology of fibrillar collagen in the ECM substantially
differently than their tamoxifen-treated counterparts. We used the
BoneJ plugin for ImageJ to quantify the thickness of fibrillar colla-
gen fibers (Fig 3B), and a custom-made algorithm based on fast
Fourier transforms (FFT) [15] to quantify the elliptical distribution
of the fibrillar collagen network that indicates fiber alignment
(Fig 3C). In this analysis, highly aligned collagen fibers exhibit
values closer to 0 (elliptical distribution in Fig 3C inset), while
◀ Figure 1. Tamoxifen decreases hypoxia and increases vascularization.A Immunofluorescence images of PDAC tissues from KPC mice treated with vehicle control of tamoxifen, scale bar 100 lm.
B–D (B, D) Quantification of GLUT1 (hypoxia marker) and CD31 (endothelial cell marker). Control (n = 5), 2 mg (n = 5), and 5 mg (n = 4). In all cases, bars represent
mean  SEM. (C) Relative values of protein levels for Glut1 in PDAC tumors assessed by proteomic analysis (6 mice for control and 2 mg and 3 mice for 5 mg, and
samples were analyzed in duplicates).
E, F Expression levels of DEGs relevant to response to hypoxia (left) and blood vessel morphogenesis (right). The values were normalized by tubulin family genes.
G Immunofluorescence images of PDAC tissues from KPC mice treated with vehicle control and 5 mg of tamoxifen, scale bar 100 lm.
H Quantification of HIF-1A in PDAC tissues. Control (n = 5) and 5 mg (n = 4). In the box-and-whisker plot, the central box represents values from the lower to upper
quartile. The middle line represents the mean. The vertical line extends from the minimum to the maximum value.
I qPCR levels of HIF-1A in PSCs, normalized to RPLP0 and relative to control.
J Western blot bands for protein expression in PSCs (p-Tmod is post-translational modification). The plot shows the quantification of the sum of band intensities
corresponding to isoform 1, isoform 2, isoform 3, and post-transcriptionally modified HIF-1A (n = 8 control and n = 8 tam).
Data information: All histogram bars represent mean  SEM; *P < 0.05, **P < 0.01, ***P < 0.001 (t-test for H and J; ANOVA and Tukey’s post hoc test for B, D, I). For (A
and G), n ≥ 5 sections per animal. Results collected during 3 or more separate experiments.
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randomly aligned fibers values close to 1 (circular distribution in
Fig 3C inset). Overall, ECM remodeled by tamoxifen-treated PSCs
showed a significant decrease in fibrillar collagen fiber diameter,
length, and alignment compared to control PSCs (Fig 3D–F).
LOX-L2 catalyses the first step in the cross-linking of collagen
bundles. In order to causally relate the decrease in the diameter
of collagen fibers under tamoxifen treatment with LOX-L2 activ-
ity, we treated PSCs with tamoxifen, rescued the treated cells
with LOX-L2, and allowed PSCs to remodel the collagen matrigel
matrices in the same manner as previously explained. Analysis
of the SHG images revealed that the diameter of the collagen
fibers in matrices remodeled by LOX-L2 rescued tamoxifen-
treated PSCs was not significantly different than the diameter of
the fibers in matrices remodeled by untreated control PSCs
(Fig 3G and H). Furthermore, a LOX-L2-specific antibody
returned the diameter of the fiber in the matrices remodeled by
tamoxifen treatment plus LOX-L2 rescued PSCs to statistically
comparable values of the diameter in matrices remodeled by
tamoxifen-treated PSCs alone.
Furthermore, the amount of collagen produced by PSCs was
downregulated at the gene and protein levels, as well as collagen
secretion (Fig 4A–D). This effect was maintained in the presence
of ER antagonist but abrogated when GPER antagonist was used.
We also observed a consistent dose-dependent downregulation of
collagen in PDAC tissues from KPC mice treated with tamoxifen
(Fig 4E). Collectively, these data show that tamoxifen reduces
collagen synthesis via GPER signaling and collagen remodeling
via LOX-L2.
Tamoxifen downregulates MMP-2 in PSCs and PDAC tissues
Matrix metalloproteinases (MMPs, also known as matrixins) are
considered the main group of ECM degrading enzymes [27]. MMPs
are a family of calcium-dependent zinc-containing endopeptidases,
of which MMP-2 and MMP-9 are the two main types secreted by
PSCs [28]. It has been reported that HIF-1Α regulates the expression
of the MMP-2 gene [29]. After observing a downregulation of HIF-
1Α levels in tamoxifen-treated PSCs, we investigated whether
tamoxifen interfered with the proteolytic remodeling ability of PSCs
through MMP-2. Tamoxifen treatment significantly downregulated
MMP-2 expression and activity in a GPER-dependent manner,
assessed by PCR and zymography (Fig 4F and G). MMPs are closely
regulated by specific endogenous tissue inhibitors of metallopro-
teinases (TIMPs), and TIMP-2 is a specific inhibitor of MMP-2 [30].
In order to test whether the changes in MMP-2 levels in PSCs under
tamoxifen treatment might be influenced by TIMP-2, we determined
the levels of expression of TIMP-2 in PSCs and observed that there
were no significant changes in TIMP-2 mRNA levels in tamoxifen-
treated PSCs in relation to untreated control PSCs (Appendix Fig
S5). We used immunohistochemistry and quantitative proteomics to
quantify the MMP-2 levels in tissues from KPC mice treated with 2
and 5 mg of tamoxifen. MMP-2 mRNA levels were significantly
decreased in a dose-dependent manner from control mice to mice
treated with 5 mg of tamoxifen (Fig 4H–J).
In order to learn more about the mechanism by which tamoxifen
decreased MMP-2 levels in PSCs, we cultured PSCs on 1 and 25 kPa
PAA matrices and observed a significant increase in MMP-2 values
◀ Figure 2. Tamoxifen reduces LOX-L2 levels in PSCs and PDAC tissues.A qPCR levels of LOX-L2 in PSCs, normalized to RPLP0 and relative to control.
B Western blot levels of LOX-L2 in PSCs (n = 3 experimental replicates).
C Expression of LOX family genes obtained from RNA-seq data in control and tamoxifen-treated PSCs (n = 3 experimental replicates). Expression value was normalized
by tubulin family genes. Asterisk means significant differences (P < 0.05). Mann-Whitney U-test.
D qPCR levels of LOX family in PSCs, normalized to RPLP0 and relative to control.
E Relative values of protein levels for LOX members in PDAC tumors assessed by proteomic analysis (6 mice for control and 2 mg and 3 mice for 5 mg, and samples
were analyzed in duplicates).
F Immunofluorescence images of PDAC tissues from KPC mice treated with vehicle (control), and 2 mg and 5 mg of tamoxifen, scale bar 50 lm.
G Quantification of LOX-L2 for images in (F). n = 5 (control), 4 (2 mg), and 3 (5 mg), and n > 10 sections per animal.
H qPCR levels of LOX-L2 and HIF-1A in PSCs, normalized to RPLP0 and relative to 1 kPa.
I qPCR levels of LOX-L2 and HIF-1A in PSCs, normalized to RPLP0 and relative to control.
J Quantification of average forces applied by PSCs on pillars. BBI = blebbistatin. In the box-and-whisker plot, the central box represents values from the lower and
upper quartile. The middle line represents the mean. The vertical line extends from the minimum to the maximum. Three experimental repeats.
K qPCR levels of LOX-L2 in PSCs, normalized to RPLP0 (60S acidic ribosomal protein P0) and relative to control.
Data information: In all cases, histogram bars represent mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (t-test for B, D, I; ANOVA and Tukey’s post hoc test for A, G, H, J,
K). For (A, D, H, I, J, and K) three replicates collected in at least three different experiments.
▸Figure 3. Tamoxifen decreases collagen fiber thickness, length, and alignment.A Images of Matrigel collagen gels previously remodeled by PSCs, second harmonic generation signal for fibrillar collagen (green) and F-actin (red), scale bar 100 lm.
B Fiber thickness color-code map in a represented through the BoneJ plugin where larger spheres fit along fibers represent greater thickness, scale bar 100 lm.
C SHG fibrillar collagen images used for calculation of alignment through the FFT algorithm. Insets show FFTs of fibrillar collagen-I images, representing alignment
with respect to the elliptical distribution of the FFT central maxima. Circular behavior (values approaching 1) represents no aligned orientation and lower values
represent fiber orientation as alignment is displayed as a power distribution orthogonal to the orientation direction. Scale bar 20 lm.
D–F Quantification of fiber thickness, length, and alignment for images in (A–C).
G Quantification of collagen fiber thickness using the BoneJ algorithm for images in (B and H).
H Representative images of Matrigel collagen gels previously remodeled by PSCs, second harmonic generation signal for fibrillar collagen (green) and F-actin (red),
scale bar 100 lm.
Data information: n ≥ 6 matrices per condition. In the scatter plot in (E), each point represents a section. In the box-and-whisker plot in (D), the central box represents
values from the lower to upper quartile. The middle line represents the mean. The vertical line extends from the minimum to the maximum value. Histogram bars (F
and G) represent mean  SEM. ***P < 0.001 (t-test for D, E, F; ANOVA and Tukey’s post hoc test for G). Three experimental replicates for all panels.
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on the stiffest matrices. MMP-2 values were significantly reduced in
tamoxifen-treated PSCs cultured in 25 kPa (Fig 4K). We used siRNA
against HIF-1A to knockdown HIF-1A expression in PSCs and found
that under these conditions, tamoxifen treatment did not reduce
MMP-2 levels beyond the values observed for PSCs transfected with
siRNA against HIF-1A (Fig 4L). We used qPCR and zymography to
A
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test the gene expression and enzymatic activity of MMP-9 produced
by PSCs, as well as immunofluorescence and quantitative proteo-
mics of PDAC tissues from control and treated KPC mice to validate
these findings in tissues. We observed no significant effect of tamox-
ifen in MMP-9 values (Appendix Fig S5). Taken together, these
results suggest that tamoxifen decreases MMP-2 via mechanical
downregulation of HIF-1A.
Fibronectin secretion by PSCs and its organization in the ECM is
modulated by tamoxifen
Together with collagen, fibronectin is the other major ECM molecule
secreted by activated PSCs into PDAC stromal tissues [12]. Fibro-
nectin is associated with LOX activity, and its expression is regu-
lated by HIF-1A [29,31]. After observing a decrease in both HIF-1A
and LOX-L2 expression with tamoxifen treatment, we sought to
study whether fibronectin expression levels were affected following
tamoxifen treatment. The fibronectin gene in cancer is regulated
through alternative splicing, implying a significant role of the post-
transcriptional regulatory mechanism for its differential expression
and function in distinct tissue types [32]. For instance, fibronectin
extra domain A (EDA) isoform is expressed in liver and breast
cancer [33], while fibronectin extra domain B (EDB) has been impli-
cated in the PDAC microenvironment [34]. Both isoforms, EDA and
EDB, are secreted by PSCs [35].
We observed a significant decrease in the levels of gene expres-
sion of fibronectin (FN) and both splicing variants (FN-EDA and
FN-EDB), and also a downregulation of FN at the protein level
when PSCs were treated with tamoxifen versus untreated controls
cells (Fig 5A and B). Likewise, when PSCs were embedded within
collagen matrigel matrices and allowed to deposit fibronectin into
the ECM for 72 h, tamoxifen-treated PSCs deposited about half the
amount of fibronectin deposited by untreated control PSCs (Fig 5C
and D). Similar to what we observed for LOX-L2 and MMP-2, PSCs
cultured on 25 kPa matrices produced more FN than PSCs cultured
on 1 kPa, and tamoxifen-treated PSCs cultured on 25 kPa
produced FN levels comparable to those of PSCs on 1 kPa. We
used siRNA against HIF-1A to knockdown HIF-1A expression in
PSCs and found that under these conditions, tamoxifen treatment
did not reduce FN levels beyond the values observed for PSCs
transfected with siRNA against HIF-1A (Appendix Fig S6). This
supports the notion of mechanical regulation of FN expression by
PSCs via HIF-1A.
We then sought to investigate whether the effect of tamoxifen on
PSCs is also observed in PDAC tissues from KPC mice treated with 2
and 5 mg of tamoxifen using immunostaining and quantitative
proteomics. We observed a significant and pronounced decrease of
FN content in a dose-dependent manner (Fig 5E, G and H). Using
the BoneJ plugin for ImageJ and custom-made algorithms, we found
that the thickness and alignment of the fibronectin fibers was signif-
icantly reduced from control untreated mice to mice treated with
5 mg of tamoxifen (Fig 5F, I and J). Collectively, these data suggest
that tamoxifen reduces FN secretion in PSCs and PDAC tissues via
mechanical downregulation of HIF-1A.
◀ Figure 4. Tamoxifen decreases synthesis and secretion of collagen and MMP-2 in PSCs and PDAC tissues.A qPCR levels of collagen in PSCs, normalized to RPLP0 and relative to control.
B Western blot analysis of collagen normalized to total protein and relative to control.
C Quantification of time-lapse collagen synthesis and deposition by PSCs.
D Representative immunofluorescent images used for the quantification in (C), scale bar 20 lm, collagen-I was assessed with a specific primary antibody staining.
E Relative values of protein levels for collagen in PDAC tumors assessed by proteomic analysis (6 mice for control and 2 mg and 3 mice for 5 mg, and samples were
analyzed in duplicates).
F qPCR levels of MMP-2 in PSCs, normalized to RPLP0 and relative to control.
G MMP-2 activity on control and tamoxifen-treated PSCs assayed by gelatin zymography; above signal intensity of the representative bands used for the
quantification presented in the plot below.
H, I Immunohistochemistry images and quantification of MMP-2 levels in PDAC tissues from KPC mice treated with vehicle (control), and 2 and 5 mg of tamoxifen,
scale bar 100 lm (n = 5 (control), 4 (2 mg), and 3 (5 mg) and n ≥ 5 sections per animal).
J Relative values of protein levels for MMP-2 in PDAC tumors assessed by proteomic analysis (6 mice for control and 2 mg and 3 mice for 5 mg, and samples were
analyzed in duplicates).
K qPCR levels of MMP-2 in PSCs, normalized to RPLP0 and relative to 1 kPa.
L qPCR levels of MMP-2 in PSCs, normalized to RPLP0 and relative to control.
Data information: Histogram bars represent mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (t-test for group of two data sets in B and G and ANOVA and Tukey’s post
hoc test for the rest). For (A, B, C, F, G, H, K, and L) 3 replicates collected in three different experiments.
▸Figure 5. Tamoxifen decreases fibronectin levels in PSCs and PDAC tissues.A qPCR levels of fibronectin (FN), fibronectin extracellular domain A (FN-EDA), and fibronectin extracellular domain B (FN-EDB) in PSCs, normalized to RPLP0 and
relative to control.
B Western blot analysis of FN normalized to total protein and relative to control.
C Quantification of fibronectin intensity density of images presented in (D).
D FN fluorescence and SHG collagen images for matrigel collagen gels remodeled by PSCs.
E Immunohistochemistry images of PDAC tissues from KPC mice treated with vehicle control, and 2 mg, and 5 mg of tamoxifen (n = 5 (control), 4 (2 mg), and
3 (5 mg), and n ≥ 5 sections per animal).
F FN fiber thickness color-code map in (E) represented through the BoneJ plugin.
G Relative values of protein levels for FN in PDAC tumors assessed by proteomic analysis.
H–J Quantification of fibronectin immunohistochemistry staining, fiber thickness, and alignment scored of images presented in (E).
Data information: In all cases, histogram bars represent mean  SEM; *P < 0.05, **P < 0.01, ***P < 0.001 (t-test for A, B, C; ANOVA and Tukey’s post hoc test for H, I, J).
For (A, B, C, H, I, and J) three replicates collected in three different experiments. Scale bars are 100 lm.
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Tamoxifen treatment decreases proliferation and increases
apoptosis in cancer cells
Cancer cells trigger HIF-1A signaling upon hypoxia conditions [8].
Having observed the hypoxia-independent mechanical regulation of
HIF-A signaling in PSCs, we sought to investigate whether the
survival of cancer cells could be affected by this regulation as well.
We used immunofluorescence of tissues from control and tamox-
ifen-treated KPC mice in which cytokeratin 19 was utilized as a
marker for epithelial cells. We observed a significant and marked
downregulation of proliferation measured through Ki67 staining and
a little over three times increase in the levels of caspase-3-mediated
apoptosis (Fig 6A and B) in the cancer cells in tissues from tamox-
ifen-treated KPC mice.
Next, we examined the in vitro effect of tamoxifen treatment on
the levels of HIF-1A and the rates of proliferation and apoptosis in
the pancreatic cancer cell line Suit2-007 under hypoxic and non-
hypoxic conditions. The levels of HIF-1A were significantly reduced
in both conditions indicating that tamoxifen can negatively regulate
HIF-1A levels in Suit-2 cells thorough a mechanism that is indepen-
dent of hypoxia (Fig 7A and B). Less surprisingly, the proliferation
rate significantly decreased and apoptosis significantly increased in
both conditions (hypoxia and non-hypoxia) (Fig 7C–F).
To gain more insights in the mechanism that regulates HIF-1A
levels in these cancer cells, we cultured Suit-2 in the soft (1 kPa)
and stiff (25 kPa) PAA matrices under non-hypoxic conditions and
observed that stiff substrates promoted transcriptional upregulation
of HIF-1A. Tamoxifen treatment reduced HIF-1A to levels compara-
ble to the ones shown in the soft matrices (Appendix Fig S7). We
also observed that Suit-2 cells expressing the constitutively active
isoform of myosin expressed significantly higher levels of HIF-1A
compared to control. Treating Suit-2 cells with blebbistatin, an inhi-
bitor of myosin activation significantly reduced the levels of HIF-A
compared to control (Appendix Fig S7). These results support the
notion that HIF-1A levels in Suit-2 cells are mechanically regulated
by mechanosensing matrix stiffness and myosin activation.
Discussion
Tamoxifen has been consistently used for many years as an anti-
estrogen hormonal therapy for estrogen-positive breast cancers, and
the implications of tamoxifen on the nuclear estrogen receptors have
been thoroughly described [36]. Here we found that tamoxifen
promotes multiple changes in PSCs and the microenvironment of
pancreatic cancer through a GPER-dependent mechanism that
induces a negative regulation of HIF-1A by decreasing actomyosin-
dependent PSC contractility and matrix stiffness mechanosensing
(Fig 8). These multiple changes involve upregulation of the number
of blood vessels in PDAC tissues.
Our data show that HIF-1A is the unifying factor through which
tamoxifen reduces the levels of LOX-L2, MMP-2, and FN in PSCs
and PDAC tissues. We note that HIF-1A may act as a converging
point to mechanically regulate the adaptive response of PDAC to
hypoxia and the overall architecture of the tumor microenviron-
ment. While hypoxia is the most common method of HIF-1A activa-
tion, upregulation of HIF-1A expression has also been seen in the
presence of oxygen, with G protein-coupled receptors on the cell
surface responding to microenvironmental cues [37]. Our observa-
tions that tamoxifen can negatively regulate HIF-1A in cancer cells
through a hypoxia-independent mechanism open up the possibility
to reprogram the mechanosensory machinery in these cells to modu-
late their proliferation under hypoxic conditions by targeting HIF-
1A.
Previous work has demonstrated that treating KPC mice with
ATRA, which induces myosin contraction-mediated mechanical
quiescence of PSCs [16], reduced hypoxia and increased vascular-
ization [18]. Another study that used the vitamin D receptor to
reprogram PSCs to quiescence also showed heightened levels of
angiogenesis [38]. PDAC tissues are notoriously known to be poorly
vascularized, which hampers drug delivery [1], and reducing stro-
mal stiffness is known to inhibit metastasis and increased drug effi-
cacy in PDAC [17]. Angiotensin inhibitors have also been proposed
to alleviate solid stress in pancreatic cancer models by reducing
collagen and hyaluronan production, resulting in increased blood
vessel density, reduced hypoxia along with improved vascular
perfusion, and increased delivery of cytotoxic drugs [6]. Interest-
ingly, a recent study has shown that PDAC metastasis to the liver
recapitulated the poorly vascularized milieu characteristic of the
primary tumor [39]. Taking into consideration this finding, we
propose that by increasing the vascular density, tamoxifen might
not only enhance drug delivery to the primary tumor but also to the
metastatic microenvironment. However, this remains to be proven
by further experiments.
Our findings are consistent with previous studies that have
reported decreased levels of MMP-2 in mammary gland tissues of
rat treated with tamoxifen [40]. Inhibition of MMP activity by
GM6001 (broad spectrum potent MMP inhibitor) in fibroblasts
prevented these cells from creating tracks in the ECM for the cancer
cells to follow [41]. Thus, tamoxifen may also play a fundamental
role in ECM remodeling of PDAC tissues by regulating the levels of
MMP-2, the predominant collagenolytic enzyme secreted by PSCs
[28]. We also observed that tamoxifen treatment reduced the thick-
ness and alignment of FN fibers. FN is instrumental in the tumor-
associated desmoplastic reaction and it has been shown that aligned
FN matrices, those that have been remodeled through force-depen-
dent myofibroblast contraction, favor cancer cell invasion [42].
Tamoxifen treatment induced a reduction in the synthesis and
secretion by PSCs of collagen, another chief ECM molecule, and
changed its content and organization in PDAC tissues. The decrease
◀ Figure 6. Tamoxifen treatment decreases proliferation and increases apoptosis in epithelial cells of PDAC tissues.A Immunofluorescence images of PDAC tissues from KPC mice treated with vehicle control, and 2 mg of tamoxifen, scale bar is 100 lm. Upper panels: Ki67 staining
is used as a surrogate of proliferation. White arrows indicate Ki67-positive nuclei in epithelial cells. Lower panels: Cc3 staining shows the cells undergoing
caspase-3-mediated apoptosis. Tamoxifen panels show higher levels of yellow staining, which indicates higher percentage of apoptotic epithelial cells.
B Quantification of staining in panel (A) (n = 4 animals per condition, and n ≥ 5 sections per animal, two experimental repetitions). Histogram bars represent
mean  SEM; ***P < 0.001, t-test.
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in the fiber thickness was causally related to the reduction in the
LOX-L2 levels, and the decreased alignment could have been
promoted by the decreased PSC contractility and tissue tension as
others have recently reported [43]. This reduction in the thickness
of collagen fibers in the presence of LOX-L2 inhibitor is also in
agreement with a previous study that used bAPN to inhibit LOX,
◀ Figure 7. Tamoxifen treatment decreases HIF-1A levels and proliferation and increases apoptosis in Suit-2 pancreatic cancer cells.A–F (A, E, F) Immunofluorescence images of control and tamoxifen-treated Suit2-007 cells, scale bars is 20 lm. Panel (A) represents HIF-1A staining in hypoxia and non-
hypoxia conditions, panels (E and F) show Ki67 and Cc3 staining as markers of proliferation and caspase-mediated apoptosis, respectively. Panel (E): red—F-actin,
green—Ki67, blue—nuclei. Tamoxifen negatively regulates HIF-1A in hypoxia and non-hypoxia conditions. (B, C, D) Quantification of immunofluorescence staining
in panels (A, E, F). For quantification, eight fields of view (n > 50 cells) per condition. Histogram bars represent mean  SEM; **P < 0.01, ***P < 0.001, t-test. All
panels include data collected during 3 independent experiments.
Figure 8. Model illustrating the pleiotropic changes of tamoxifen in PSCs and PDAC stroma.
Top panel: In PSCs, tamoxifen reduces actomyosin contractility via GPER. This mechanically downregulates HIF-1A that is the unifying factor through which tamoxifen
reduces LOX-L2, MMP-2, and FN. GPER activation reduces the synthesis and secretion of collagen by PSCs. Tamoxifen also impairs LOX-L2 collagen remodeling. The red color
has been used to highlight the two main pillars by which tamoxifen acts on PSCs. Bottom panel: In PDAC tissues, tamoxifen reduces response to hypoxia and increases
vascularization, and also reduces the amount and organization of collagen and FN in the ECM.
14 of 22 EMBO reports 20: e46557 | 2019 ª 2018 The Authors
EMBO reports Biomechanical signature of tamoxifen Ernesto Cortes et al
Published online: December 11, 2018 
which led to a significant reduction in the fibrillar collagen diameter
in mouse tissues [44] and another independent study that used a
LOX-L2 antibody to revert ECM remodeling by myofibroblast-
secreted LOX-L2 [45]. Increased collagen deposition, alignment, and
fiber thickness are promoted by PSCs in PDAC [4,11,13]. Interest-
ingly, two recent studies also found thicker and more aligned colla-
gen fibers adjacent to the PDAC tumors, as well as augmented
levels of myosin activation in PDAC tissues from those patients with
the shortest survival [4,46]. Taken together, these data underscore
collagen topology as a pivotal contributor to the ECM mechanics in
PDAC and suggest that treating PSCs with tamoxifen may restore
mechanical homeostasis in pancreatic tissues to resolve PDAC-asso-
ciated fibrosis. It has been recently shown that PDAC cells use colla-
gen fragments as a nutritional source [47]. Therefore, the effect of
tamoxifen on decreasing collagen synthesis by PSCs does not only
alleviate fibrosis, but also might hamper cancer cells survival under
nutrient limited conditions.
In an accompanying report in this issue [48], we show that
tamoxifen inhibits the myofibroblastic differentiation of pancreatic
stellate cells and their ability to remodel the tumor microenviron-
ment in PDAC via a mechanotransduction mechanism that involves
GPER and YAP. Our observations that tamoxifen inhibits fibro-
nectin, collagen, and HIF-1A expression suggest other links between
hypoxia and mechanotransduction. Mechanical induction of HIF-1A
has been observed in endothelial cells exposed to low shear stress
[49], and in the myocardium in response to mechanical stress [50].
The altered ECM generated by HIF-1A activity may promote activa-
tion of the transcriptional regulator YAP through mechanotransduc-
tion.
Other mechanisms for how HIF-1A activates YAP, and vice versa,
have been previously demonstrated. Firstly, HIF-1A upregulates
expression of GPRC5A, a GPCR, which then promotes YAP nuclear
localization through RhoA [51]. Secondly, HIF-1A and YAP have
been shown to colocalize in the nucleus, where YAP facilitates HIF-
1A in promoting the upregulation of the PKM2 gene. PKM2
promotes the switch from oxidative phosphorylation to lactate
generation in glycolysis under hypoxic conditions [52,53]. Enhanced
glycolysis is a hallmark of PDAC, where the hypoxia induced by
tumor growth necessitates the switch from oxidative phosphoryla-
tion to hypoxic lactate production [53]. This positive feedback loop
suggests the importance of a drug which can inhibit both compo-
nents. YAP activity has been shown to promote PDAC indepen-
dently of KRas mutations [54], and hence, this proposed feedback
cycle may be integral to this phenomenon. However, since Ras lies
upstream of HIF-1A [55], these mechanisms may also be active in
KRas-dependent tumors.
GPER-mediated activation of HIF-1A might be more dominant
in vivo as HIF-1A-mediated gene expression can promote YAP in
multiple ways, through GPRC5A and/or through modulation of the
extracellular environment. Conversely, YAP is a transcriptional co-
activator for HIF-1A to promote glycolysis, and depending on the
strength of activation and the importance of glycolysis for PDAC
progression, GPER downregulation of YAP activity may also facili-
tate HIF-1A activity.
Several previous attempts to use anti-angiogenic therapies in
PDAC have failed [56–58], and given that the hypovascular environ-
ment of PDAC is not directly linked to hypoxia [9], our work lays
the groundwork for future questions. GPER agonists could modulate
the fibrovascular stroma of PDAC to increase vascular density and
perfusion by reducing overall solid stress (through collagen and FN)
which would increase intratumoral drug perfusion, while concur-
rently impeding the adaptive fitness of tumor and stromal cells to
survive under hypoxic conditions (via HIF-1A) and thus promoting
widespread hypoxic necrosis.
Tamoxifen is a drug with well-established pharmacodynamics
and safety. Given the pleiotropic effects of estrogenic signaling, the
ubiquitous expression of GPER across different tissues, and the
numerous pathways that lie downstream of GPCR signaling, we
suggest that tamoxifen may lead a new strategy for drug repurpos-
ing to reprogram the tumor microenvironment.
Materials and Methods
Mice
KPC mice (Pdx-1 Cre, KrasG12D/+, p53R172H/+) were randomized to
three groups and were injected (IP) with either: (i) vehicle [corn
oil], (ii) 2 mg, or (iii) 5 mg of tamoxifen daily starting the same day
when PDAC tumor was detected and continuing until mice reached
endpoint (for most mice between 8–14 days). After the treatment,
mice were sacrificed and pancreatic tissues harvested and used for
further analysis. Animals were maintained in conventional animal
facilities and monitored daily. All studies were conducted in compli-
ance with the UK Home Office guidelines under license and
approved by the local ethical review committee.
Cell culture and reagents
Primary, cultured-activated human PSCs (passages 6–8, male
gender) were purchased from ScienCell Research Laboratories
(Carlsbad, USA) and cultured in DMEM/F-12 Ham (Sigma-Aldrich,
USA) with 2%FBS (Gibco, Life Technologies, USA), 50 units/ml
penicillin and 50 lg/ml streptomycin (Sigma-Aldrich, USA), and
5 ml Fungizone (Gibco, Life Technologies, USA). Tamoxifen (Z-4-
hydroxytamoxifen, cat. H7904 Sigma-Aldrich, USA) was prepared in
ethanol, and PSCs were treated with 5 lM tamoxifen (or with
ethanol vehicle-only) under dim light conditions for 10 days. Media
was replenished every 72 h. Cell culture under hypoxic conditions
was carried out in anaerobic workstations with oxygen-deprived
atmosphere and temperature controlled at 37°C. ER and GPER
antagonists were purchased from Tocris and used at 1 lM,
ICI182780 (cat. 1047), G15 (cat. 3678). Blebbistatin was from
Calbiochem, USA, and UK used at a concentration of 50 lM; human
plasma fibronectin (FC010) was from Millipore, USA. siRNA for
HIF-1A (cat. Sc-35561) was from Santa Cruz Biotechnology, USA.
pEGFP-MRLC1 T18D, S19D (constitutively active MLC-2) was a gift
from Tom Egelhoff (Addgene plasmid # 35682). All cell lines were
tested for mycoplasma contamination.
Proteomic analysis
Sample preparation
Chemicals were from Sigma-Aldrich unless otherwise mentioned.
Water was purified with Milli-Q water purification system (Milli-
pore). The samples were thawed, transferred into tubes with 1 mm
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zirconia beads (BioSpec Products), and weighed, after which 100 ll
of 8 M urea was added. The samples were homogenized with
FastPrep-24 5G homogenizer (MP Biomedicals), followed by sonica-
tion and removal of insoluble cell debris by centrifugation. Total
protein content of the samples was determined using Thermo Pierce
BCA Protein Assay Kit (Thermo Scientific), and the results were
measured with CLARIOstar plate reader (BMG Labtech). For further
sample preparation, the amount of homogenate equivalent to
100 lg of total protein was taken from each sample in duplicate,
followed by dilution to 500 ll with 50 mM ammonium bicarbonate
(Fluka Chemie AG). From these dilutions, duplicate pooled QC
samples were made, so that the amount of total protein in each
sample was 95 lg. Cysteine residues were reduced with dithiothre-
itol and carbamidomethylated with iodoacetamide. The pH of the
samples was adjusted to > 7 with 1 M ammonium bicarbonate,
followed by overnight digestion with sequencing grade modified
trypsin (Promega). After the digestion, the samples were acidified
with 10% trifluoroacetic acid and purified using C18 MicroSpin
Columns (The Nest Group Inc.) according to the manufacturer’s
instructions. LC-MS grade solvents (VWR International) were used.
The purified samples were evaporated to dryness in a vacuum
centrifuge and stored in 20°C until the LC-MS analysis.
LC-MS
The samples were resolubilized with sonication in 30 ll of 0.1% tri-
fluoroacetic acid, 1% acetonitrile in LC-MS grade water. Pooled QC
samples were used to determine the suitable injection amount
(4.0 ll) before the analysis and to monitor system stability through-
out the analysis. The LC-MS analysis was done with EASY-nLC 1000
coupled to Q Exactive MS using Xcalibur version 3.1.66.10 (Thermo
Scientific). 4.0 ll of tryptic peptide solution, equivalent to approxi-
mately 12 lg of total digested protein, was injected into the LC and
separated with Thermo Acclaim C18 columns (pre-column: PepMap
100, 75 lm × 2 cm; analytical column: PepMap RSLC,
75 lm × 15 cm). Flow rate was 300 nl/min, and the linear gradients
were as follows: 120 min from 5 to 35% of buffer B, followed by
5 min from 35 to 80% of B, 1 min from 80 to 100% of B, and 9 min
column wash with 100% of B (A: 1% acetonitrile, 0.1% formic acid,
0.01% trifluoroacetic acid in water; B: 1% water, 0.1% formic acid,
0.01% trifluoroacetic acid in acetonitrile). Mass spectrometry was
carried out using top10 data-dependent acquisition, in which the ten
most intense ions from one MS1 full scan (resolution 70,000) were
subjected to CID and analyzed in MS2 (resolution 17,500). Samples
were run in randomized order, with each sample followed by two
wash runs, and four pooled QC samples throughout the analysis.
Data analysis
Pooled QC samples, used to monitor system stability, were assessed
first but excluded from the final data analysis. Proteins were identi-
fied (1% FDR [false discovery rate] on peptide and protein level)
with Andromeda search engine [59], and protein quantification was
performed with MaxQuant software [60,61]. The search was done
against up-to-date Mus musculus UniProtKB/Swiss-Prot proteome
with mass tolerance of 6 ppm in MS1 and 20 ppm in MS2, with the
maximum of two missed cleavages [62]. LFQ (label-free quan-
tification) intensity was used without further normalization.
Contaminant and decoy matches were omitted before the statistical
analysis.
To allow statistical testing, missing values were imputed by
adding normally distributed noise (mean = non-zero minimum for
each protein divided by 100; SD = mean divided by 100) to the LFQ
intensity data. Protein abundance comparison was done using 2-
tailed unpaired t-tests and FDR multiple hypothesis correction. The
changes with P < 0.05 were considered statistically significant. GO
analysis was done with DAVID 6.8 [63, 64].
RNA sequencing and data analysis
RNA sequencing
Three biological replicates were prepared for control and treated
PSCs. The initial quality check of the control and treated samples
was performed using Bioanalyzer and Qubit. RIN values were 10 for
the six samples. Sequencing libraries were prepared using a TruSeq
Stranded mRNA Library Prep Kit from Illumina. All six samples
were pooled together and run on Nextseq500 using 1 × 75 bp read
type.
Data processing
Sequenced reads were trimmed by Trim Galore with “-q 30” option
and then mapped to a reference human genome (GRCh38.p10)
using STAR [65] with default option. Gene counts data were
obtained by quantification from the aligned data using feature-
Counts [66]. The following genes were used for data normalization
(TUBA1A, TUBA1B, TUBA1C, TUBA3D, TUBA3FP, TUBA4A, TUBB,
TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4B, TUBB6, TUBD1,
TUBE1, TUBG1, TUBG2). First, RPKM (reads per kilo-base per
million) values were calculated from obtained gene counts data,
and then, RPKM values for each encoding gene were compared
between control and tamoxifen-treated samples using the Mann–
Whitney U-test (wilcox.exact function in statistical software R).
There were no significant differences for these genes in control and
tamoxifen-treated PSCs. The smallest obtained P-value was 0.1
(Appendix Table S1). Therefore, the gene counts data were normal-
ized using the genes encoding tubulin encoding genes RUVSeq [67].
Subsequently, normalized gene expression data were analyzed by
edgeR [68], and genes with false discovery rate < 0.01 were identi-
fied as differential expression genes (DEG).
Gene ontology (GO) analysis of DEGs: GO analysis was imple-
mented in R package clusterProfiler [69]. Initially, DEGs were classi-
fied into upregulated and downregulated DEGs based on their log2
fold change values. GO enrichment analysis was carried out by
enrichGO function with the following parameters (ont = “BP”,
pAdjustMethod = “BH”, pvalueCutoff = 0.01, qvalueCutoff = 0.01).
To reduce the redundancy of enriched GO terms, simplify function
was used with the following parameters (cutoff = 0.5,
by = “qvalue”, select_fun = min). For visualization, dotplot func-
tion was used with the following parameters (x = “count”,
showCategory = 15, colorBy = “qvalue”).
RT–PCR
Total RNA was extracted with RNeasy Mini Kit (Qiagen, 74104),
and 1 lg of total RNA was reverse transcribed by High-Capacity
RNA-to-cDNA Kit (Applied Biosystems, 4387406) according to
manufacturer’s instructions. qPCR was performed with SYBR Green
PCR Master Mix (Applied Biosystems, 4309155) with 100 ng cDNA
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input in 20 ll reaction volume. RPLP0 (60S acidic ribosomal protein
P0) expression level was used for normalization as a housekeeping
gene. The sequences were as following: RPLP0 (F) 50-CG
GTTTCTGATTGGCTAC-30; RPLP0 (R) 50-ACGATGTCACTTCCAC
G-30; COL1 (F) 50-GCTATGATGAGAAATCAACCG-30; COL1 (R)
50-TCATCTCCATTCTTTCCAGG-30; LOX (F) 50-CAACATTACCACAG
TATGGATG-30; LOX (R) 50-TAGTCACAGGATGTGTCTTC-30; LOX-L1
(F) 50-ATTGTCCAATCCTGATCTCC-30; LOX-L1 (R) 50-GAATCCC
TGTGGCATC-30; LOX-L2 (F) 50-GATGTACAACTGCCACATAG-30;
LOX-L2 (R) 50-GACAGCTGGTTGTTTAAGAG30;LOX-L3 (F) 50-A
GGAAACTACATTCTCCAGG-30; LOX-L3 (R) 50-ACCCAGATTC
TATGTCCATC-30;LOX-L4 (F) 50-CTACTACAGGAAAGTCTGGG-30;
LOX-L4 (R) 50-TCCAGAAGGAGTTCTTATTCG-30; HIF-1A (F) 50-AA
AATCTCATCCAAGAAGCC-30; HIF-1A (R) 50-AATGTTCCAATTCC
TACTGC-30; HIF-2A (F) 50-CAGAATCACAGAACTGATTGG-30; HIF-
2A (R) 50-TGACTCTTGGTCATGTTCTC-30; VEGFA (F) 50-AATG
TGAATGCAGACCAAAG-30; VEGFA (R) 50-GACTTATACCGGG
ATTTCTTG-30; VEGFB (F) 50-GAAAGTGGTGTCATGGATAG-30;
VEGFB (R) 50-ATGAGCTCCACAGTCAAG-30; MMP-2 (F) 50-T
CTCCTGACATTGACCTTGGC30; MMP-2 (R) 50-CAAGGTGCTG
GCTGAGTAGATC30; MMP-9 (F) 50-TTGACAGCGACAAGAAGTGG30;
MMP-9 (R) 50-GCCATTCACGTCGTCCTTAT30; TIMP-2 (F) 50-A
GAAATATTGGACTTGCTGC-30; TIMP-2 (R) 50-GCTTGTCAACTTT
CAACAAC-30. FN1 (F) 50-CCATAGCTGAGAAGTGTTTTG-30; FN1
(R) 50-CAAGTACAATCTACCATCATCC-30; fibronectin-EDA (F) 50-TC
CAAGCGGAGAGAGT-30, fibronectin-EDA (R); 50-GTGGGTGTGAC
CTGAG-30, fibronectin-EDB (F) 50 -CCACCATTATTGGGTACCGC-30;
fibronectin-EDB (R) 50-CGCATGGTGTCTGGACCAATG-30. All
primers were used at 300 nM final concentration. The relative gene
expression was analyzed by comparative 2DDCt method.
Western blotting and zymography
Cells were washed with chilled PBS and lysed in either Triton X-100
buffer (150 mM sodium chloride, 1% Triton X-100, and 50 mM Tris–
HCl, pH 8) or RIPA (Radio Immuno Precipitation Assay) buffer
(150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, and 50 mM Tris–HCl, pH 8) containing 1 mM activated
Na3VO4 and protease inhibitors (Complete mini, Roche). Lysate was
collected using a cell scraper, disrupted by repetitive trituration
through a 25-gauge needle, and incubated for 30 min on ice with peri-
odic mixing. This was followed by centrifugation at 12,000 g for
20 min at 4°C. The protein concentration in supernatant was deter-
mined using a BCA protein assay kit (Fisher Scientific, UK). Cell
lysates were mixed with 4× Laemmli buffer (Bio-Rad) and denatured
by heating at 100°C for 5 min. Samples then were loaded into a 4–
20% Mini-PROTEAN TGX Precast Gel (Bio-Rad), and proteins were
transferred to nitrocellulose membranes (Bio-Rad). Protein on
membranes was stained using REVERT total protein stain (LI-COR) as
per manufacturer’s instructions, and blots were imaged using an
Odyssey infrared imaging system. The stain was removed using
REVERT Reversal Solution (LI-COR), followed by washing in Tris-
buffered saline (TBS). The membranes were blocked in Odyssey
blocking buffer (LI-COR) for 1 h followed by overnight incubation
with primary antibodies (rabbit anti-collagen type I, ab34710, 1:1,000;
rabbit anti-fibronectin, ab2413, 1:1,000 (both Abcam); rabbit anti-
MMP-2, sc-10736, 1:500 (Santa Cruz Biotechnology)) in 0.1% Tween
in TBS (TBST). After further washes in TBST, blots were incubated
for 1 h with secondary antibodies (Donkey anti-rabbit 680RD or
Donkey anti-rabbit 800CW, 1:15,000, LI-COR). Membranes were
washed again in TBST and imaged using an Odyssey infrared Imaging
system (LI-COR). Total protein for normalization and target protein
expression were quantified using Image Studio Lite (Version 5.2, LI-
COR). Target protein was normalized to total protein per lane and
presented relative to the control group. For LOX-L2, the cell lysates
were prepared with radio immunoprecipitation assay (RIPA) buffer
(Sigma, R0278) containing proteinase inhibitors (Sigma, P4340). The
protein concentration was quantified by DC protein assay (Bio-Rad,
500-0113) according to manufacturer’s instructions. Samples were
separated by an SDS–PAGE gel under reducing conditions and trans-
ferred to a nitrocellulose membrane (GE Healthcare, 10401196), then
blocked with 5% bovine serum albumin (BSA, Sigma, A8022)—0.1%
Tween-20 (Sigma, P1379) in PBS. LOX-L2 primary antibody (Santa
Cruz Biotechnology sc-48724 1/100 diluted) was prepared in blocking
solution and incubated overnight at 4°C. The membrane was washed
and incubated with horseradish peroxidase (HRP)-conjugated
secondary antibodies in blocking solution for 1 h at room tempera-
ture. Finally, the membrane was washed and developed with HRP
substrate (Millipore, WBLUR0100). For the cases in which the total
protein was used as reference.
For the zymography experiments, PSCs were cultured on poly-
acrylamide gels for 24 h prior to replacing culture medium with
serum-free medium, DMEM/Nutrient Mixture F-12 Ham (D8437,
Sigma) for a further 24 h. After 24 h, this medium was removed
and added to non-reducing Laemmli buffer. For gelatine zymogra-
phy, recombinant human MMP-2 (PF037, Calbiochem) and recom-
binant human MMP-9 (PF038, Calbiochem) were prepared as stock
solutions of 10 lg/ml and diluted with sterile H2O to a final concen-
tration of 10 and 20 ng/ml, respectively, and added to non-reducing
Laemmli buffer. Samples were run and developed according to the
protocol reported for zymography by Toth & Fridman [70]. Assayed
gels were photographed with a UVP Biospectrum 500 Imaging
System. Band digestion intensity representing, potential MMP activ-
ity, was calculated using the densitometry plugin for ImageJ.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) blocks were sectioned at
4 lm. Deparaffined and rehydrated with histoclear (National diag-
nostics, HS-200) followed by decreased concentrations of ethanol,
heat-induced antigen retrieval was done by boiling the sections in
10 mM sodium citrate buffer, pH = 6, for 20 min in microwave (for
MMP-2 no antigen retrieval was done). Endogenous hydrogen
peroxide activity was quenched with 0.3% H2O2 in Methanol for
30 min at room temperature. Sections were blocked with normal
serum for 1 h at room temperature and incubated with primary anti-
bodies diluted in blocking serum overnight at 4°C in a humidified
chamber. Primary antibody dilutions are as follows: FN (Abcam,
ab2413, 1/250), MMP-2 (Abcam, ab37150, 1/500). Primary antibod-
ies were washed with PBS, and biotinylated secondary antibodies
were diluted 1/250 in PBS and incubated for 30 min at room
temperature then washed. Sections were incubated with avidin layer
(VECTASTAIN Elite ABC Kit, Vector laboratories, PK-6100) for
30 min at room temperature then developed with Peroxidase
Substrate (DAB substrate Kit, Vector laboratories, SK-4100). Finally,
sections were counterstained with hematoxylin (Abcam, ab128990),
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dehydrated by increasing concentration of ethanol and histoclear,
and then mounted in DPX mountant (Sigma, 06522). In order to
analyze FN staining, the staining was selected from raw images
(with hematoxylin) by using IHC toolbox plugin by Fiji. Stain-
selected images were thresholded then converted into binary. FN
fibril thickness was analyzed on thickness maps which were created
with BoneJ plugin on stain-selected images. The alignment score of
each image was determined by using custom-made Matlab code.
Staining intensities were measured with color deconvolution.
Immunofluorescence
Cells were fixed with 4% PFA, blocked, and permeabilized with 2%
BSA and 0.1% Triton X-100 (all Sigma-Aldrich, St. Louis, MO,
USA), and then incubated with primary antibodies (Fibronectin
ab2413, Abcam, UK) 1/100 diluted in 2% BSA for 1 h at RT, then
washed with PBS and incubated with secondary antibodies (Alexa
Fluor 488 anti-rabbit, Rhodamine RedTM-X goat anti-mouse, both
Life Technologies, USA) and phalloidin (Alexa Fluor 546, A22283,
Life Technologies, USA) 1/400 diluted in PBS for 45 min in dark.
Collagen-I antibody (abcam UK, ab34710 1/100 dilution). HIF-1
alpha antibody (abcam UK, ab2185 1/200 dilution). Ki67 antibody
(abcam UK, ab15580 1/200 dilution). Caspase-3 antibody (abcam
UK, ab13847 1/100 dilution). Finally the coverslips were mounted
with ProLong Gold Antifade with DAPI (Life Technologies, USA).
For LOX-L2 staining (FFPE), blocks were sectioned, deparaffined,
and rehydrated as described previously. Antigen retrieval was done
by incubating the sections in boiled citrate buffer pH = 6 for 1 h.
LOX-L2 antibody (Santa Cruz Biotechnology sc-66950,1/50) and
aSMA antibody (Abcam, UK, ab7817, 1/50), and secondary goat
anti-mouse AlexaFluor 488 (Life Technologies, Paisley, UK; A-
11029, 1/200) and goat anti-rabbit AlexaFluor 546 (Life Technolo-
gies, Paisley, UK; A-11035 1/200) antibodies were used.
For immunofluorescent staining of GLUT1 and CD31 in pancreatic
tissues, 6-lm frozen sections were fixed in ice-cold acetone, washed in
PBS, and blocked with 10% goat serum (Sigma-Aldrich, St. Louis,
MO) and 20 lg/ml AffiniPure Fab goat anti-mouse IgG fragment (Jack-
son ImmunoResearch Laboratories, Suffolk, UK) for 1 h and 30 min,
respectively. Sections were incubated with primary antibodies against
GLUT1 (Merk Millipore, UK; 07-1401 1/500) and CD31 (Abcam,
Cambridge, UK; ab56299 1/200) in 1% BSA and 0.3% Triton X-100
(both from Sigma-Aldrich, St. Louis, MO) overnight at 4°C. Primary
antibodies were washed with 0.1% Triton X-100 and replaced with
goat anti-rabbit AlexaFluor 546 (Life Technologies, Paisley, UK; A-
11035 1/200) and goat anti-rat AlexaFluor 488 (Life Technologies,
Paisley, UK; A11006 1/200) for 1 h at room temperature. Slides were
counterstained with Hoechst 33342 (Life Technologies; 1/10,000) and
mounted with Prolong Gold (Life Technologies). Sections were imaged
with an inverted epifluorescent microscope (Motic AE31 with Moticam
5.0 MP camera) in ≥ 5 200× fields. For GLUT1 stain mean fluorescent
intensity, all images were captured using the same exposure settings
and processed with ImageJ uniformly across all groups. Image correc-
tion for the representative images was similarly kept consistent.
Micropillar video microscopy and traction force measurements
Pillar arrays were coated with human plasma fibronectin (10 lg/ml;
Sigma) and incubated at 37°C for 1 h prior to measurements. Cells
that had been trypsinized prior to measurements were suspended in
culture media and plated onto the pillar substrates. Time-lapse
imaging of the pillars was conducted with an inverted microscope
(Eclipse Ti; Nikon) operating in bright-field mode with the samples
held at an ambient temperature of 37°C. Image sequences were
recorded with an sCMOS camera (Neo sCMOS Andor) at 0.5 Hz
using a 40× (0.6NA, air; Nikon) objective over the late spreading
phase (90 min < t < 120 min). The position of each pillar in the
time-lapse videos was tracked using a custom MATLAB program to
track the center of a point spread function of the intensity of the
pillars across all frames. By selecting a location free of cells, tracking
of a small set of pillars allowed a measurement of the stage drift to
be obtained and corrected for in the data set. The time-dependent
displacement of a given pillar was obtained by subtracting the initial
position of the pillar (zero force) from the position in a given frame.
Traction forces were obtained by multiplying the pillar displace-
ments by the pillar stiffness, and the maximum for each pillar was
found to obtain the peak forces across the cell.
3D ECM remodeling assay
To analyze the ECM remodeling ability of PSCs (control or tamox-
ifen-treated), Collagen-I (BD Biosciences, 354249, stock concentra-
tion 9.37 mg/ml) and Matrigel (BD Biosciences, 354234, stock
concentration 9 mg/ml) mixture gels were prepared with 1 part
10× DMEM (Sigma, D2429) and 1 part FBS (Gibco, 10500), yield-
ing to a final concentration of 4.5 mg/ml Collagen-I and 2 mg/ml
Matrigel. The gel mixture was neutralized with 1M NaOH (Sigma,
S8045), and then, 5 × 105 cells were embedded in gels in culture
media. 80 ll gel volume was added per well of a 96-well plate
which was pre-treated with 2% BSA (Sigma, A8022) for 1 h,
washed with PBS, and air-dried for 10 min. Gels were set 1 h at
37°C and then incubated with culture media for 3 days at 37°C.
For SHG microscopy, gels were prepared as explained above. After
3 days of incubation at 37°C, gels were fixed with 4%
paraformaldehyde (PFA) (Sigma, P6148) in PBS for 1 h at 37°C,
then washed with PBS and permeabilized with 0.3% Triton X-100
(Sigma, T8787) in PBS for 30 min. After that, gels were blocked
with 1% BSA 0.1% Triton X-100 in PBS for 1 h. Gels were washed
with PBS and stained with Alexa Fluor 546-conjugated Phalloidin
at 1/300 dilution in 1% BSA in PBS for 30 min. Finally, gels were
washed two times with PBS.
Multiphoton microscopy
All SHG images were obtained using a custom-built multiphoton
microscope incorporating an upright confocal microscope (SP5,
Leica) and a mode-locked Ti:Sapphire Laser (Mai Tai, Newport
Spectra-Physics). Images of the SHG signal from collagen-I were
collected using an 820 nm excitation with SHG signal obtained with
a 414/46 nm bandpass filter and multiphoton autofluorescence
signal obtained with a 525/40 nm bandpass filter. A 25×, 0.95 NA
water-immersion objective (Leica) was used to deliver the excitation
signal and to collect the SHG emission signal from the sample.
Images with a 620 × 620 lm field of view were obtained with 2,048
pixel resolution and a line rate of 10 Hz giving a pixel resolution of
~0.3 lm with 3× averaging on each acquisition to reduce the effect
of noise.
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Analysis of multiphoton images
SHG images obtained through multiphoton microscopy were
analyzed to quantify collagen properties of Matrigels after remodel-
ing. For the assessment of collagen concentration, SHG images
obtained for collagen were analyzed in ImageJ for the intensity
density across fields of view of 200 lm, taking 5 regions of interest
from each full field of view (620 lm). Intensity density values from
35 images were analyzed with the software Prism (GraphPad) for
histogram representation. Nonparametric t-tests were conducted on
the datasets via the Mann–Whitney showing the significant dif-
ferences between the datasets. SHG images acquired for the imaging
of collagen in Matrigels were further analyzed to quantify the orien-
tation of the collagen fibrils. Using the 200 lm field of view images
used for intensity density analysis, each image was split into
4 × 100 lm images in ImageJ. Using the fast Fourier transform
(FFT) module, all frequencies represented in an image could be
represented as a power plot. By fitting an ellipse to the FFT plot, the
ratio between the long and short axis of the ellipse could be used to
obtain the eccentricity of the plot, where circular behavior (values
approaching 1) represents no aligned orientation and lower values
represent fiber orientation as alignment is displayed as a power
distribution orthogonal to the orientation direction [15]. Eccentricity
values were plotted in Prism Software and significance analyzed
through the Mann–Whitney nonparametric t-test.
LOX-L2 rescue
To re-introduce LOX-L2 expression in tamoxifen-treated PCSs, PSCs
were treated with 5 lM tamoxifen for 10 days, then transfected with
1.5 lg LOX-L2 plasmid (DNASU plasmid repository bank) for 4 h by
using JetPRIME reagent (1:3 DNA:jetPRIME ratio (w/v)) and
JetPRIME buffer (Polyplus, 114-15). During transfection, cells were
cultured in 2 ml media without tamoxifen to exclude the possibility
of it affecting the transfection efficiency. After transfection, culture
media was changed with 2 ml media containing tamoxifen. Mock
transfection was done by using JetPRIME reagent and buffer only
(i.e., without DNA), and the cells were otherwise treated the same
way as the transfection group. Functional assays were done 48 h
after transfection. To study the effect of LOX-L2 over-expression on
ECM remodeling, LOX-L2 over-expressing tamoxifen-treated PSCs
and mock transfection group were trypsinized and 500,000 cells
were embedded in 80 ll Collagen-I Matrigel mixture gels (4.5 and
2 mg/ml final concentration, respectively). After 1-h incubation at
37°C on 2% BSA-treated wells of 96-well plate, gels were covered
with tamoxifen containing media and left to be remodeled 3 days at
37°C. In order to block LOX-L2 activity, gels were treated with LOX-
L2 blocking antibody during the matrix remodeling process (Santa
Cruz Biotechnology sc-48724, Clone:N-15).
Statistical analysis
All statistical analyses were conducted with the Prism graphical
software (GraphPad, Software, La Jolla, CA). Data were generated
from multiple repeats of different biological experiments in order
to obtain the mean values and standard errors (SEM) displayed
throughout. P-values have been obtained through t-tests on paired
or unpaired samples with parametric tests used for data with a
normal distribution and nonparametric tests conducted via the
Mann–Whitney U-test where data had a skewed distribution.
Significance for the t-tests was set at P < 0.05 where graphs show
significance through symbols (*P < 0.05; **P < 0.01;
***P < 0.001).
Data availability
The proteomics analysis data have been deposited in the PeptideA-
tlas under the reference PASS01070. The PSCs RNA sequencing data
have been deposited in the European Nucleotide Archive, accession
number ERP023834.
Expanded View for this article is available online.
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